Movement Alert｜WUXI BIO Rises 3.07% in Regular Trading, CXO Sector Rallies on Accelerating Industry Recovery

Market Focus07-31

On July 31, WUXI BIO rose 3.07% in regular trading, trading at 38.96 HKD/share, with turnover of 399 million HKD.

The gain was driven by a broad-based recovery across the pharmaceutical outsourcing (CXO) sector. Multiple CXO names rallied in tandem, with Insilico up 10.08%, GenScript Biotech up 6.63%, XtalPi up 8.70%, WuXi AppTec up 2.16%, and WuXi XDC up 1.57%. The sector rebound follows improving domestic innovative drug investment and financing, continued momentum in novel drug modalities, and expectations that CRO/CDMO new order signings and earnings will accelerate, driving the CXO industry chain into a new growth phase.

Additionally, the CXO sector has entered an earnings realization period, with several peers releasing strong H1 performance pre-announcements. Global innovative drug primary market financing reached 267.5 billion USD in H1, up 58.5% year-over-year, providing further tailwinds. WUXI BIO is scheduled to report its interim results on August 25.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199823139?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 13:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199823139","market":"hk","top_or_hot":-1,"title":"Movement Alert｜WUXI BIO Rises 3.07% in Regular Trading, CXO Sector Rallies on Accelerating Industry Recovery","media":"Market Focus","content":"<p><p>On July 31, WUXI BIO rose 3.07% in regular trading, trading at 38.96 HKD/share, with turnover of 399 million HKD.</p><p>The gain was driven by a broad-based recovery across the pharmaceutical outsourcing (CXO) sector. Multiple CXO names rallied in tandem, with Insilico up 10.08%, GenScript Biotech up 6.63%, XtalPi up 8.70%, WuXi AppTec up 2.16%, and WuXi XDC up 1.57%. The sector rebound follows improving domestic innovative drug investment and financing, continued momentum in novel drug modalities, and expectations that CRO/CDMO new order signings and earnings will accelerate, driving the CXO industry chain into a new growth phase.</p><p>Additionally, the CXO sector has entered an earnings realization period, with several peers releasing strong H1 performance pre-announcements. Global innovative drug primary market financing reached 267.5 billion USD in H1, up 58.5% year-over-year, providing further tailwinds. WUXI BIO is scheduled to report its interim results on August 25.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WUXI BIO Rises 3.07% in Regular Trading, CXO Sector Rallies on Accelerating Industry Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WUXI BIO Rises 3.07% in Regular Trading, CXO Sector Rallies on Accelerating Industry Recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-31 13:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 31, WUXI BIO rose 3.07% in regular trading, trading at 38.96 HKD/share, with turnover of 399 million HKD.</p><p>The gain was driven by a broad-based recovery across the pharmaceutical outsourcing (CXO) sector. Multiple CXO names rallied in tandem, with Insilico up 10.08%, GenScript Biotech up 6.63%, XtalPi up 8.70%, WuXi AppTec up 2.16%, and WuXi XDC up 1.57%. The sector rebound follows improving domestic innovative drug investment and financing, continued momentum in novel drug modalities, and expectations that CRO/CDMO new order signings and earnings will accelerate, driving the CXO industry chain into a new growth phase.</p><p>Additionally, the CXO sector has entered an earnings realization period, with several peers releasing strong H1 performance pre-announcements. Global innovative drug primary market financing reached 267.5 billion USD in H1, up 58.5% year-over-year, providing further tailwinds. WUXI BIO is scheduled to report its interim results on August 25.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1199823139","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199823139","pubTimestamp":1785475293,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 31, WUXI BIO rose 3.07% in regular trading, trading at 38.96 HKD/share, with turnover of 399 million HKD.The gain was driven by a broad-based recovery across the pharmaceutical outsourcing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"走势提醒|药明生物常规交易上涨3.07%，CXO板块因行业加速复苏而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"On July 31, WUXI BIO rose 3.07% in regular trading, trading at 38.96 HKD/share, with turnover of 399 million HKD.The gain was driven by a broad-based recovery across the pharmaceutical outsourcing (CXO) sector. Multiple CXO names rallied in tandem, with Insilico up 10.08%, GenScript Biotech up 6.63%, XtalPi up 8.70%, WuXi AppTec up 2.16%, and WuXi XDC up 1.57%. The sector rebound follows improving domestic innovative drug investment and financing, continued momentum in novel drug modalities, and expectations that CRO/CDMO new order signings and earnings will accelerate, driving the CXO industry chain into a new growth phase.Additionally, the CXO sector has entered an earnings realization period, with several peers releasing strong H1 performance pre-announcements. Global innovative drug primary market financing reached 267.5 billion USD in H1, up 58.5% year-over-year, providing further tailwinds. WUXI BIO is scheduled to report its interim results on August 25.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199823139","isCrawlerRequest":true}